Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 23 Jan 2017
At a glance
- Drugs Glesatinib (Primary)
- Indications Gastric cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions
- Sponsors MethylGene; Mirati Therapeutics
- 17 Jan 2017 Planned End Date changed from 1 Mar 2017 to 1 Aug 2017.
- 17 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.
- 05 Jan 2017 Results from this study (Data as of December 2, 2016) published in a Mirati Therapeutics media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History